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Flow Cytometric microsphere-based immunoassays (FloCMIA), involving polystyrene 
microspheres adsorbed with glutamic acid decarboxylase (GAD65) fused to thioredoxin 
(TrxGAD65), are used to assess GAD65 autoantibodies (GADA) in diabetic patients’ sera. 
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Abstract 
The first measurable sign of arising autoimmunity in Type 1 Diabetes Mellitus is the detection of 
autoantibodies against beta-cell antigens, such as glutamic acid decarboxylase (GAD65). GAD65 
autoantibodies (GADA) are usually measured by Radioligand Binding Assay (RBA). The aim of 
this work was to develop protocols of Flow Cytometric microsphere-based immunoassays 
(FloCMIA) which involved glutamic acid decarboxylase fused to thioredoxin (TrxGAD65) 
adsorbed on polystyrene microspheres. Detection of bound GADA was accomplished by the use of 
anti-human IgG-Alexa Fluor 488 (Protocol A), anti-human IgG-biotin and streptavidin-
dichlorotriazinyl aminofluorescein (DTAF) (Protocol B) or TrxGAD65-biotin and streptavidin-
DTAF (Protocol C). Serum samples obtained from 46 patients assayed for routine autoantibodies at 
Servicios Tecnológicos de Alto Nivel (STAN-CONICET) were analyzed by RBA, ELISA and three 
alternative FloCMIA designs. Protocol C exhibited the highest specificity (97.8%) and sensitivity 
(97.4%) and a wide dynamic range (1.00-134.40 SDs). Samples obtained from 40 new-onset 
diabetic patients were also analyzed to further evaluate the performance of protocol C. The latter 
protocol showed a sensitivity of 58.6% and a prevalence of 47.5%. Two patients resulted positive 
only by FloCMIA protocol C and its SDs were higher than RBA and ELISA, showing a 
significantly wide dynamic range. In conclusion, FloCMIA proved to be highly sensitive and 
specific, requiring a low sample volume; it is environmentally adequate, innovative and it 
represents a cost-effective alternative to traditional GADA determination by RBA and/or ELISA; 
making it applicable to most medium-complexity laboratories. 
Key words 
Flow Cytometry, Diabetes Mellitus, glutamic acid decarboxylase autoantibody, immunoassay 
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1. Introduction 
Type 1 Diabetes Mellitus (T1DM) is classified as an organ-specific T-dependent autoimmune 
disease since it is caused by the autoimmunity-mediated destruction of pancreatic islet beta cells, 
leading to absolute dependence of exogenous insulin to control hyperglycemia 
1
. The clinical 
presentation of this disease is preceded by an asymptomatic period in which detection of 
autoantibodies against a wide variety of beta-cell antigens is the first measurable sign of arising 
autoimmunity. There are four major autoantibodies that support diagnosis of T1DM 
2, 3
: 
insulin/proinsulin autoantibodies (IAA/PAA), glutamic acid decarboxylase 65 kDa isoform 
autoantibodies (GADA), insulinoma-associated tyrosine phosphatase 2 autoantibodies (IA-2A) and 
Zinc transporter isoform 8 autoantibodies (ZnT8A). About 98% of children and adolescents with 
new-onset T1DM and approximately 10% of adult-onset diabetic patients present at least one of 
these autoantibodies 
4, 5
, thus the possibility to detect these markers facilitates both the prediction of 
T1DM in children and a more precise classification of adult-onset diabetic individuals. 
The above mentioned autoantibodies are usually measured by Radioligand Binding Assay (RBA) 
3, 
6-8
, which is considered the reference method. However, this methodology requires radioactive 
tracers employing [
125
I] or [
35
S]-Methionine, making this method environmentally inappropriate, 
expensive and limited to authorized laboratories. In order to replace radiometric fluid-phase assays 
such as RBA, solid phase tests such as Enzyme-Linked ImmunoSorbent Assays (ELISA) have been 
developed in numerous designs 
9, 10 , 11-13
. Nevertheless, ELISAs are not as sensitive and specific as 
RBA which leads to misdiagnosis of a considerable proportion of patients. Despite this drawback, 
ELISA is more frequently employed than RBA for the determination of  GADA , and hence many 
kits or in-house designs are used. These approaches are feasible when a handy source of glutamic 
acid decarboxylase 65 kDa isoform (GAD65) is available for immobilization to microplates (i.e, 
recombinant protein obtained from modified prokaryotic cells). In this sense, we have previously 
described the expression of human GAD65 in Escherichia coli as a soluble and properly folded 
fusion protein with thioredoxin (TrxGAD65) 
14
. This method has allowed us to determine the 
presence of GADA by ELISA
12
, with a similar format to that of Palomer et al 
15
. This assay depends 
on the ability of divalent autoantibodies to form a bridge between immobilized TrxGAD65 and 
biotinylated TrxGAD65 present in the fluid phase. However, this in-house design did not overcome 
the disadvantages of solid phase assays since it was reported 52% sensitivity and 94.6% specificity 
in the Diabetes Autoantibody Standardization Program (DASP) 2009. 
Even though Flow Cytometry (FC) has primarily been designed for multiparametric cellular 
analyses, this methodology can be employed to detect any particle in the lower micron range by 
laser light scattering. Inert microspheres of different sizes are considered suitable solid supports for 
antibody-antigen interactions 
16
. In fact, FC has been historically considered an alternative 
analytical platform for the development of immunoassays 
17
 applicable to detection and 
quantification of soluble analytes using fluorochrome-conjugated antibodies. Moreover, FC-based 
methods have been proved advantageous for the simultaneous detection of multiple analytes 
18
. 
The aim of the present work was to develop highly sensitive and quasi-quantitative alternative 
protocols of Flow Cytometric microsphere-based immunoassays (FloCMIA) for the detection of 
GADA. 
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2. Experimental 
2.1. Human sera collection 
Blood samples were collected from patients after overnight fasting and the corresponding sera were 
stored at -20ºC until assayed. Forty six sera showing a wide range of GADA positivity by RBA 
were selected from the samples collected in our laboratory during routine autoantibodies 
determination (Servicios Tecnológicos de Alto Nivel, STAN-CONICET). Besides, 40 sera from 
children and adolescents with newly diagnosed T1DM (diagnosed according to WHO criteria 
19
) 
were also collected. The protocols were approved by the Ethical Committees of the J. P. Garrahan 
Pediatric Hospital of Buenos Aires. Written consent from all participants involved in this study and 
parental consent in the case of minors, was obtained. 
Normal human control sera were obtained from healthy subjects without personal or family history 
of autoimmune disease. The collection of serum samples was approved by the Ethics Committee of 
the Clinical Hospital José de San Martín, University of Buenos Aires. 
 
2.2. Detection of GADA by RBA 
2.2.1. Production of [
35
S]-GAD65 tracer 
The tracer [
35
S]-GAD65 was obtained by in vitro transcription/translation of cDNA encoding the 
human GAD65 using a rabbit reticulocyte lysate system (Promega, Madison, WI, USA) in the 
presence of [
35
S]-Methionine (New England, Nuclear, Boston, MA, USA), according to the 
manufacturer´s instructions. Translation products were diluted in RBA buffer (0.02 M Tris-HCl, 
0.15 M NaCl, pH 7.4, 0.1% V/V Tween 20) and applied to a PD10 column (Pharmacia-LKB 
Biotechnology, Uppsala, Sweden) in order to remove free [
35
S]-Methionine. 
2.2.2. RBA protocol 
RBA was performed as previously described 
7
 with minor modifications 
11
. Briefly, 2.5 µL of 
human sera were incubated overnight at 4°C with 10,000 cpm of [
35
S]-GAD65 in a final volume of 
60 µL in RBA buffer. After that, 50 µL of protein A-Sepharose 4B FF (GE Healthcare Biosciences, 
Uppsala, Sweeden) in RBA buffer (2:3) were added to isolate immunocomplexes, and incubated 2 h 
at room temperature on an end-over-end shaker. Subsequently, samples were allowed to settle and 
the supernatants were discarded.  Pellets were washed three times with 200 µL of RBA buffer and 
once with 200 µL of 0.2 M NaCl in RBA buffer.  Finally, pellets were suspended in 100 µL of 1% 
w/V SDS and supernatants were carefully transferred to vials for scintillation counting (1 min/tube). 
Results for each sample were calculated as Bound% (B%) = 100 x (bound cpm/total cpm), and 
expressed as Standard Deviation scores (SDs) = (B% - Bc%) /SDc where Bc% is the mean B% of 
control sera and SDc its standard deviation. Twenty human control sera were included in each assay. 
Samples were considered positive when SDs > 3. This assay had 79.6% sensitivity and 98% 
specificity in the DASP 2007. 
2.3. Detection of GADA by ELISA 
2.3.1. Reagents 
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Lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.0) was used in the TrxGAD65 
expression protocol. Phosphate saline buffer (PBS, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, 0.14 M 
NaCl, 2.7 mM KCl, and pH 7.4) was used for microplate coating. A 3% w/V skim milk in PBS 
(PBS-M) and PBS containing 0.05% V/V Tween 20 (PBS-T) were used as blocking solution and 
wash buffer, respectively. Sample or reagent dilutions were prepared in 3% w/V skim milk in 
0.05% V/V PBS–Tween 20 (PBS-M-T). Avidin-HRP was purchased from Jackson 
ImmunoResearch Laboratories, Inc. and 3, 3’, 5, 5’-tetramethyl-benzidine/H2O2 (TMB, GE 
Healthcare, Uppsala, Sweden) was employed as the chromogenic substrate. 
2.3.2. Expression of TrxGAD65 in Escherichia coli and biotinylation 
The fusion protein TrxGAD65 was expressed in E. coli as previously described 
14
. Briefly, E. coli 
GI698 was transformed with pGAD65 (Trx). Bacteria were cultured at 30°C in 0.2% w/V casein 
amino acids, 0.5% w/V glucose, 1 mM MgCl2 and 100 µg/mL ampicillin. Protein expression was 
induced with 2 mL of 10 mg/mL tryptophan overnight at 20°C. Bacteria from 200 mL culture were 
collected by centrifugation, suspended in 2 mL of lysis buffer and sonicated in the presence of 1 
mM 2-mercaptoethanol (2ME) and protease inhibitors (0.1% w/V aprotinin and 2 mM 
phenylmethylsulfonyl fluoride) over crushed ice. After sonication, Triton X-100 was added to a 
final concentration of 0.1% V/V and incubated for 10 min at 0°C. The soluble intracellular fraction 
was then separated by centrifugation at 15,000 rpm for 10 min. The fusion protein was purified by 
affinity chromatography following the protocol previously described 
20
. The resin was based on an 
agarose support covalently modified with phenylarsine oxide, which permitted the binding of 
proteins containing vicinal dithiol residues 
21
. Bound proteins were eluted with two-column 
volumes of lysis buffer containing 100 mM 2ME. A typical TrxGAD65 preparation yielded 9 mg of 
80-90% pure TrxGAD65 per Liter of culture. The fusion protein was stored in a mixture of 50% 
V/V glycerol, 0.2 mM pyridoxal 5-phosphate, 0.05% V/V Tween 20 and 0.1% w/V aprotinin. Two 
milliliters of the purified fusion protein were subjected to buffer exchange to PBS using a ZEBA 
desalt spin column (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturers’ 
instructions. The desalted protein was then incubated for 2 h at 0°C with 0.32 mg of sulfo-NHS-
biotin (Pierce Biotechnology, Rockford, IL, USA) and free biotin was removed on a new ZEBA 
desalt spin column. Storage conditions for TrxGAD65-biotin were the same as those for 
TrxGAD65. 
2.3.3. ELISA protocol 
The protocol employed was the same as that previously described 
12
 with minor modifications. 
Except when otherwise indicated, incubations were at room temperature, washing steps were 
performed with 200 µL of PBS-T and 50 µL/well were added in each incubation step. Polystyrene 
microplates (Maxisorp, NUNC, Roskilde, Denmark) were coated overnight at 4°C with TrxGAD65 
purified preparation diluted 1/50 in PBS, washed 3 times with 200 µL of PBS, blocked for 1.5 h 
with 200 µL of PBS-M, and washed 5 times. Samples were added and microplates were incubated 
for 1 h. All samples and blanks were assayed in duplicate. After incubation with samples, plates 
were washed 5 times and TrxGAD65-biotin diluted 1/300 was added. After another 1 h incubation, 
plates were washed 5 times and bound TrxGAD65-biotin was detected by the addition of Avidin-
HRP diluted 1/500.  After 1 h incubation, microplates were washed 4 times plus 1 final washing 
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step with 200 µL of PBS, TMB was added and incubated 15 min in the dark. The color reaction was 
stopped with 2 M H2SO4 and the oxidized substrate was measured at 450 nm in an ELISA plate 
reader Multiskan ex (Thermo electron corporation, Vantaa, Finland). Results were calculated as 
specific absorbance (As, mean of each sample minus the mean of blank wells), and expressed as 
SDs = (As - Ac) /SDc, where Ac is the mean specific absorbance of control sera and SDc its standard 
deviation. The cut-off value of the assay was SDs > 3. 
2.4. Detection of GADA by FloCMIA 
2.4.1. Passive adsorption of microspheres with TrxGAD65 
2.4.1.1. Reagents 
 Isotonic buffered saline (IBS) (2.3 mM NaH2PO4, 14.2 mM Na2HPO4, 0.14 M NaCl, 3.8 mM KCl, 
3.1 mM sodium azide) was used as buffer for passive adsorption. For blocking free sites a solution 
of 0.5% w/V bovine serum albumin in IBS (IBS-BSA) was employed. The washing and storage 
buffer was PBS containing 0.02% w/V sodium azide (PBS-SA). Polystyrene microspheres were 
purchased from Spherotech, Inc. (Lake Forest, IL, USA). These particles are prepared by using 
conventional emulsion polymerization process with styrene as the monomer and benzoyl peroxide 
as polymerization initiator without any cross-linking agent (making them mainly hydrophobic). 
Microspheres have been precleaned using centrifugation and their size was determined visually by 
Scanning Electron Microscope and/or Beckman Coulter Multisizer. 
2.4.1.2. Passive adsorption protocol 
This protocol was performed using the manufacturer’s instructions with minor modifications.  
Microspheres (4 µm, 36.4 µL of 5% w/V suspension) were mixed in 0.5 mL Eppendorf tubes with 
28 µg TrxGAD65 purified preparation per 100 cm
2
 of microspheres in a final volume of 220 µL in 
IBS, and incubated overnight at 4°C on an end-over-end shaker. The preparation was centrifuged at 
10,000 rpm for 10 min and the supernatant was discarded. The pellet was suspended with 220 µL of 
IBS-BSA and incubated for 1 h at room temperature on an end-over-end shaker. The preparation 
was centrifuged again at 10,000 rpm for 10 min, the supernatant was discarded and the pellet was 
washed with 400 µL of PBS-SA. Finally, another 400 µL of PBS-SA were added (resulting in 1x10
5
 
microspheres-TrxGAD65/µL) and the suspension was stored at 4°C. 
2.4.1.3. Stability study of TrxGAD65-microspheres 
In order to determine if conformational non-continuous epitopes were properly folded after 
adsorption onto the microspheres, the GAD enzymatic activity was carried out measuring the 
formation of 
14
CO2 from decarboxylation of L-[
14
C(U)]-glutamic acid to form gamma-aminobutyric 
acid (GABA)
14, 22
. Briefly, 2 µL L-[
14
C(U)]-glutamic acid (New England Nuclear, Life Science 
Products, Inc., Boston, MA, USA) were assayed in glass tubes with 50 µL of samples (PBS as 
negative control, TrxGAD65 preparation as positive control, and microspheres-TrxGAD65 as 
samples) in 200 µL of activity buffer (50 mM K3PO4, 1 mM EDTA, 1 mM 2-
aminoethylisothiouronium bromide, 0.2 mM pyridoxal 5-phosphate, 20 mM glutamic acid, pH 7.2). 
A small piece of 3MM Whatman paper, soaked with 50 µL of 1 M hyamine in methanol was 
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introduced into the reaction tube. After 1 h incubation at 37°C, 0.25 mL of 2.5 M H2SO4 was 
injected into the solution to stop the reaction. The mixture was incubated for 1 h at 37°C to ensure 
the complete evolution of CO2 and its absorption to hyamine. Papers were transferred to vials 
containing 2 mL of scintillation fluid and 
14
CO2 was determined in a liquid scintillation counter. 
Results were expressed as a sample cpm/blank cpm ratio. 
2.4.2. FloCMIA protocols 
2.4.2.1. Reagents 
PBS was used as compatible buffer for Flow Cytometric acquisition, the washing buffer was PBS-T 
and sample or reagent dilutions were prepared using 0.5% w/V BSA in 0.05% V/V PBS –Tween 20 
(PBS-BSA-T). Goat anti-human IgG-Alexa Fluor 488 was purchased from Molecular probes; Inc. 
(Eugene, OR, USA) and rabbit anti-human IgG-biotin and streptavidin-dichlorotriazinyl 
aminofluorescein (DTAF) were purchased from Jackson ImmunoResearch Laboratories, Inc. 
2.4.2.2. Protocol A 
Except when otherwise indicated, all washing steps were performed with 200 µL of PBS-T on a 
MultiscreenHTS vacuum manifold (Millipore Corporation, Billerica, MA, USA). Fifty microliters of 
sample diluted 
1
/5 in PBS-BSA-T were mixed with 20 µL of microsphere-TrxGAD65 preparation 
(2.5x10
3
 microspheres/µL) in 0.2 mL tubes. Incubation was performed in 2 steps: i) 3 h at room 
temperature and ii) overnight at 4°C, both on an end-over-end shaker. After the incubation step, 
mixtures were transferred to a MultiscreenHTS-HV 96-well filtration plate (Millipore Ireland BV) 
and washed 5 times. For detection of bound antibody, 50 µL of goat anti-human IgG-Alexa Fluor 
488 diluted 1/500 was used and plates were incubated for 1 h at room temperature in the dark. After 
that, plates were washed 4 times plus 1 final washing step with 200 µL of PBS and microspheres 
were suspended with another 200 µL of PBS. The suspension was transferred to Röhren-tubes (3.5 
mL, 55x12 mm, Sarstedt, Germany) and acquired on a PAS III PARTEC Flow Cytometer 
(PARTEC, Görlitz, Germany) equipped with a 488 nm Argon laser. Samples were analyzed using 
Cyflogic software (CyFlo Ltd., Turku, Finland), singlet population of microspheres was gated in 
forward scatter (FSC) vs. side scatter (SSC) dot plot, fluorescence signals were measured in FL1 
channel and reported as median fluorescence intensities (MFI) (Electronic Supplementary Figure 1). 
Results were expressed as SDs = (MFIs - MFIc) /SDc where MFIs is the mean MFI of samples in 
duplicate, MFIc is the mean MFI of control sera and SDc its standard deviation. Twenty human 
control sera were included in each assay and samples were considered positive when SDs > 2. The 
schematic description of this protocol is shown in Fig. 1 and Electronic Supplementary Figure 2. 
2.4.2.3. Protocol B 
This design was similar to protocol A, except that 20 µL of sample diluted ¼ in PBS-BSA-T were 
mixed with 20 µL of microsphere-TrxGAD65 preparation (5x10
3
 microspheres/µL) and directly 
incubated overnight at 4°C on an end-over-end shaker. In this case, detection of bound antibodies 
required a two-step incubation (1 h at room temperature each, with 5 washes in between): i) 50 µL 
of rabbit anti-human IgG-biotin diluted 1/500 was added and ii) 50 µL of streptavidin-DTAF 
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diluted 1/150 were used for amplification of the antigen-antibody interaction. Samples were 
considered positive when SDs > 2. The schematic description of this protocol is shown in Fig. 1 and 
Electronic Supplementary Figure 2. 
2.4.2.4. Protocol C 
This was similar to protocol A, except that 20 µL of pure human serum were mixed with 20 µL of 
microsphere-TrxGAD65 preparation (3.125x10
3
 microspheres/µL) and directly incubated overnight 
at 4°C on an end-over-end shaker. As described above, detection of bound antibodies required a 
two-step incubation (1 h at room temperature each, with 5 washes in between): i) 50 µL of 
TrxGAD65-biotin diluted 1/50 was added and ii) 50 µL of streptavidin-DTAF diluted 1/100 were 
used for detection of bound TrxGAD-biotin. Samples were considered positive when SDs > 3. The 
schematic description of this protocol is shown in Fig. 1 and Electronic Supplementary Figure 2. 
Fig. 1. Schematic representations of alternative FloCMIA protocols for GADA detection. Four 
µm microspheres-TrxGAD65 were used as the solid phase.  
2.5. Statistical analysis 
To assess if data from control subjects were normally distributed, the D'Agostino & Pearson 
omnibus normality test was applied. Inter-assay correlation was assessed by standard linear 
regression. Differences between results obtained with FloCMIA protocols vs. RBA or ELISA were 
evaluated by the Wilcoxon matched-pairs signed rank test. In order to remove outliers from 
normally distributed control sera the Grubbs’ test was performed. Calculations were performed 
using GraphPad Prism version 6.01 for Windows (GraphPad Software, San Diego California, USA, 
www.graphpad.com). 
3. Results and discussion 
3.1. Selection and characterization of STAN-CONICET sera 
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3.1.1. Detection of GADA by RBA and ELISA 
Forty six sera from the STAN-CONICET were analyzed in parallel by RBA and ELISA. In the 
detection of  GADA by RBA, SDs, used as precision units for inter-assay comparison purposes, 
ranged from 9.06 to 67.99, median SDs = 47.86 (Fig. 2. a and Table 1). The RBA for the 
determination of GADA in clinical samples was partially replaced in our laboratory by a non-
radiometric method such as ELISA. The rationale for this replacement was to avoid the use of 
radioactive isotopes in routine methods because of their cost, their low stability and because they 
are environmentally harmful. Disadvantages, as the prior mentioned, resulted in difficulty of 
implementation in low complexity laboratories. Out of the 46 GADA positive sera by RBA, 32 
scored positive by ELISA, whereas 14 patients were negative (Fig. 2. b). These results indicated 
that ELISA had a relative sensitivity of 69.6% for this sera collection (percentage of patients RBA 
positive that were ELISA positive) and 100% specificity when analysis of control human sera was 
performed (calculated as 100% minus the percentage of false positives). These data are similar to 
those reported previously 
12
. The ELISA showed SDs ranging from 0.11 to 10.03, and a median SDs 
= 5.02 (Table 1). As previously described, the ELISA protocol relies on GADA crosslinking of 
immobilized TrxGAD65 and fluid phase TrxGAD65-biotin, resulting in a highly specific method 
but with lower sensitivity than RBA. For this reason it was considered as a first line method for 
screening purposes (for instance, negative results may be reexamined by RBA). Furthermore, it 
showed a narrow dynamic range and lower GADA titers than those obtained by RBA. Several 
ELISA procedures for the detection of GADA have previously been reported 
10, 15, 23-27
 but most of 
them have presented lower sensitivity than the reference RBA 
28-30
. This finding appears to be due to 
a relative inability of these assays to distinguish true low levels of GADA in T1DM patients from 
unspecific signal levels in normal control sera. It could have been due to modifications of the 
epitopes created by interaction and a partial or complete denaturation of the antigen adsorbed to the 
solid phase plastic matrix. Epitopes would be modified since adsorption onto solid phases can 
expose regions of the protein that were hidden in the native form. Proteins adsorbed to solid 
surfaces may undergo some conformational change because of their relatively low structural 
stability and their tendency to unfold allowing the formation of additional interaction points with 
the surface. For this reason, the amount of GADA bound could be decreased since they are mainly 
directed against discontinuous conformational epitopes. 
Assay 
Median Range Sensitivity
a
 Specificity
b
 
(SDs) (SDs) (%) (%) 
RBA 47.86 9.06-67.99 100 100 
ELISA 5.02 0.11-10.03 69.6 100 
FloCMIA 
    
A 2.32 (-1.69)-10.05 56.5 91.4 
B 3.08 (-1.19)-18.07 63.0 94.9 
C 23.60 1.00-134.40 97.4 97.8 
a
 Percentage of patients RBA positive that were positive by each method 
b
 100% - percentage of false positive 
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Table 1. Analytical parameters from normal human sera and patients’ sera from STAN-
CONICET. The results were obtained by RBA, ELISA and FloCMIA protocols A, B and C. 
3.1.2. Detection of GADA by FloCMIA protocols 
The aim of this  study was to improve the analytical performance of methods employed in the 
determination of humoral markers, with considerably repercussion in terms of diagnostic support 
for autoimmune Diabetes and socioeconomic impact associated with this medical specialty. Our 
group has developed a new analytical method based on the use of microspheres as a solid phase and 
a Flow Cytometer as the platform for detection and data acquisition. In this work we introduce the 
development of three different protocols for the determination of GADA by FC, named FloCMIA. 
To the best of our knowledge, no studies evaluating the detection of GADA by FloCMIA-like 
methods have been published so far. The biggest challenge for this type of assays is the low 
concentration of autoantibodies frequently present in sera from patients with T1DM (~1.10
-12
 M for 
GADA). That is the reason for requiring a highly sensitive method, such as FC, which relies in 
fluorescence detection. 
3.1.2.1. Stability study of TrxGAD65-microspheres 
The GAD enzymatic activity was evaluated in TrxGAD65 preparation, both previous (ratio = 4.76) 
and after (ratio = 10.67) the adsorption protocol. This demonstrated that the structure of the 
molecule was correctly folded at least in the proximity of the catalytic site, even when the 
recombinant enzyme was immobilized on a polystyrene surface. 
3.1.2.2. FloCMIA protocol A 
Protocol A was based on a standard design for detection of antibodies, similar to an indirect ELISA. 
The reporter antibody was conjugated to Alexa fluor 488, a fluorochrome of comparable excitation 
and emission spectra to fluorescein. This protocol also used a limited volume of sera (equivalent to 
10 µL of undiluted sample), higher than that used in RBA (2.5 µL of undiluted sera), but much 
lower than those habitually reported in ELISAs (≈ 50 µL). Control sera (n= 35) results showed two 
different statistical populations that needed outliers removal by the Grubbs’ test. Remaining results 
were normally distributed. Outliers removed by the Grubbs’ test were included in all FC plots and 
specificity calculations, as they are considered false positives. For this alternative, specificity was 
91.4%. In order to achieve maximum analytical sensitivity for this protocol, SDs > 2 was chosen as 
the cut-off value for positive results. Twenty six GADA positive sera by RBA scored positive when 
evaluated by FloCMIA protocol A, whereas 20 patients were negative (Fig. 2. c i.). These results 
showed a sensitivity of 56.5%, SDs ranging from -1.69 to 10.05 and a median SDs = 2.32 (Table 1). 
Neither its analytical sensitivity nor its specificity was adequate for clinical applications. Besides, it 
showed a narrow dynamic range in comparison with RBA. 
3.1.2.3. FloCMIA protocol B 
Upon trying to improve the results obtained with protocol A, an alternative protocol B was 
developed using the same basic design but including an amplification step. This step consisted in 
the use of a xenogeneic antibody conjugated with biotin, while the fluorochrome (DTAF) was 
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covalently bound to streptavidin. As biotin-streptavidin is one of the strongest non-covalent 
interactions usually employed in immunochemistry and each antibody is conjugated with several 
biotin residues, the detection of GADA was expected to be more distinguishable than signals from 
control sera. After outlier removal from control sera (n = 39) by the Grubbs’ test, remaining results 
were normally distributed. Specificity for this protocol was 94.9% and its sensitivity was 63.0% 
when a cut-off for positive results of SDs > 2 was chosen. Thus 29 GADA positive sera by RBA 
scored positive when evaluated by FloCMIA protocol B, whereas 17 patients were negative (Fig. 2. 
c ii.). This assay exhibited signals ranging from -1.19 to 18.07 SDs and a median SDs = 3.08 (Table 
1). Results showed that, in fact, sensitivity and specificity were increased, as well as the dynamic 
range, even though a smaller sample volume was used (20 µL of diluted sample, equivalent to 4 µL 
of sera). Although these parameters were better than the ones obtained with protocol A, they were 
still not as good as expected for replacement of RBA and/or ELISA. 
 
Fig. 2. GADA results from normal human sera (controls) and diabetic patients’ sera from 
STAN-CONICET. The results, expressed as SDs, were obtained by RBA (a), ELISA (b) and 
FloCMIA protocols (c, i. protocol A, ii. Protocol B and iii. Protocol C). The cut-off value for each 
assay is indicated by a dotted line. 
3.1.2.4. FloCMIA protocol C 
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In order to improve FloCMIA’s output, and considering the acceptable performance of ELISA for 
clinical applications in routinely GADA determination, FloCMIA’s protocol C was developed. This 
design was similar to that of ELISA-based determination of GADA because it relies on GADA 
crosslinking of immobilized TrxGAD65 on the microsphere surface and fluid phase TrxGAD65-
biotin. For this protocol, outlier removal from control sera (n = 38) by the Grubbs’ test left a 
normally distributed population. This method exhibited a specificity of 97.8% and a sensitivity of 
97.4% for a cut-off of SDs > 3. This meant that 45 GADA positive sera by RBA scored positive 
when evaluated by FloCMIA protocol C, whereas just one patient was negative (Fig. 2. c iii.). 
Furthermore, SDs values (median SDs = 23.60 and range = 1.00-134.4) were higher than any 
derived from the other FloCMIA protocols, or even RBA and ELISA, exhibiting a wide dynamic 
range (Table 1). This alternative protocol forced GADA to interact using its two paratopes, 
decreasing the unspecific signal when compared to other FloCMIA protocols. Such design, 
combined with Streptavidin-DTAF for fluorescence detection, resulted in the highest sensitivity, 
specificity and wider dynamic range observed for any of FloCMIA alternatives. Although this 
protocol required the use of a higher volume of patients’ sera (20 µL of undiluted sample), it was 
still smaller than the volume normally used in ELISA.  
Fig. 3. Integrated GADA results for diabetic patients’ sera from STAN-CONICET. The results 
obtained by RBA, ELISA, and FloCMIA protocol A (a), protocol B (b) and protocol C (c) are 
presented as Venn’s diagrams. 
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3.1.3. Integrated results 
Venn’s diagrams (Fig. 3) depict the integrated results of RBA, reference ELISA, and FloCMIA 
protocols A, B and C. As shown in panel (a), 22 out of 46 sera were positive by RBA, ELISA and 
FloCMIA protocol A. Ten sera were only positive by both RBA and ELISA, while 4 were only 
positive by both RBA and FloCMIA protocol A. As shown in panel (b), 24 out of 46 sera were 
positive by all RBA, ELISA and FloCMIA protocol B. Here, 8 sera were only positive by both 
RBA and ELISA, while 5 were only positive by both RBA and FloCMIA protocol B. Lastly, panel 
(c) shows that 32 out of 46 sera were positive by all RBA, ELISA and FloCMIA protocol C. 
Moreover, the latter was able to detect 13 patients positive by RBA, while ELISA could not. All of 
these results made protocol C the best candidate so far for replacement of RBA and/or ELISA for 
GADA assessment. 
Fig. 4. GADA results from normal human sera (controls) and children and adolescents with 
newly diagnosed T1DM. The results, expressed as SDs, were obtained by RBA (a), ELISA (b) and 
FloCMIA protocol C (c). The cut-off value for each assay is indicated by a dotted line. 
3.2. GADA detection in new-onset Type 1 diabetic patients 
3.2.1. Detection of GADA by RBA, ELISA and FloCMIA protocol C 
Taking into account that results from tests performed on STAN-CONICET samples showed an 
adequate approach for the determination of GADA, protocol C was selected to evaluate new-onset 
diabetic patients. Forty sera from children and adolescents with T1DM were tested in parallel by 
RBA, ELISA and FloCMIA protocol C. These sera showed a wide range of reactivity expressed as 
SDs, when RBA was performed (ranging from -0.41 to 64.76, median SDs = 17.37) (Table 2). For 
this population, 29 sera scored positive by RBA (Fig.4. a), observing a considerable number of 
borderline sera. Thus, the reference method demonstrated a representative prevalence of 72.5% in 
this population (percentage of Type 1 diabetic patients GADA positive from the total population 
studied), in agreement with previous reports (70-80%) 
5, 33-36
. On the other hand, 17 GADA positive 
sera by RBA scored positive when evaluated by ELISA, whereas 23 patients were negative (Fig. 4. 
b). These results showed that ELISA had a sensitivity of 58.6%; and a prevalence of 42.5% (SDs 
from -1.18 to 12.25, median SDs = 0.99) (Table 2), not near to those for RBA, but similar to data 
previously reported for this method 
10, 12
. When evaluated by FloCMIA protocol C, the prevalence 
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of positive results for this population was 47.5% and the relative sensitivity obtained was 58.6% 
(median SDs = 2.375), a value that was lower than that for RBA. The lower sensitivity showed by 
FloCMIA could be a consequence of partial denaturation of TrxGAD when adsorbed on the surface 
of polystyrene microspheres, as discussed for ELISA. Nevertheless, we presented evidence that the 
structure of the molecule was correctly folded since the immobilized enzyme maintained its 
activity. However, when a comparison was made with ELISA, FloCMIA achieved a slightly higher 
prevalence. Seventeen GADA positive sera by RBA scored also positive by FloCMIA protocol C, 
meanwhile 2 sera resulted positive only by FloCMIA protocol C. Again, SDs for sera were higher 
than RBA and ELISA (SDs from -1.49 to 152.1), showing a significantly wide dynamic range 
(Table 2).  
Assay 
Median Range Sensitivity
a
 Prevalence
b
 
(SDs) (SDs) (%) (%) 
RBA 17.37 (-0.41)-64.76 100 72.5 
ELISA 0.99 (-1.18)-12.25 58.6 42.5 
FloCMIA 
    
C 2.38 
(-1.49)-
152.10 
58.6 47.5 
a
 Percentage of patients RBA positive that were positive by each method 
b
 Percentage of GADA positive patients from the total population studied 
Table 2. Analytical parameters from normal human sera and sera from children and 
adolescents with newly diagnosed T1DM. The results were obtained by RBA, ELISA and 
FloCMIA protocol C. 
3.2.2. Integrated results and correlation analysis 
Venn’s diagrams (Fig. 5) illustrate integrated results of RBA, ELISA and FloCMIA protocol C. 
Twenty-nine sera were positive by RBA, while 11, resulted negative (27.5%). However, 2 of these 
RBA negative sera showed GADA positivity by FloCMIA protocol C, not being considered false 
positives since the sera had been obtained from newly diagnosed patients with T1DM. In this sense, 
it is currently accepted that RBA alone is not enough to rule out the existence of GADA in 
childhood diabetic patients 
37
. Fifteen sera were positive by all RBA, ELISA and FloCMIA 
methods, whereas 10 were only positive by RBA and 9 were negative by all methods. Furthermore, 
FloCMIA was able to detect RBA positive sera that ELISA was not. 
When correlation plots for RBA and ELISA vs. the corresponding parallel determinations 
performed by FloCMIA protocol C were analyzed, the statistic parameters obtained were: r
2
 = 
0.2815 for RBA and FloCMIA, and r
2
 = 0.6712 for ELISA and FloCMIA. To further assess the 
correlation between FloCMIA protocol C and the two conventional methods, paired data were 
subjected to a Wilcoxon matched-pairs signed rank test: the Spearman’s correlation coefficient (rs = 
0.6650 for RBA and FloCMIA, and rs = 0.7766 for ELISA and FloCMIA) and P value (P < 0.0001 
for both analysis) showed that the pairing was not significantly effective and there was not an 
acceptable concordance between methods. FloCMIA protocol C joined solid phase and fluid phase-
like interactions due to polystyrene microspheres, probably enabling antigen-GADA linkage 
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(though it did not significantly correlate with a solid phase method or with a fluid phase one). 
Despite the fact that FloCMIA could not detect every low titer GADA sera (determined by RBA), 
as seen also for ELISA, it revealed high signals for many sera with low/medium GADA titers as 
shown in the correlation analysis between RBA and FlocMIA. Since GADA was successfully semi-
quantified by FloCMIA in most sera that were sent to our laboratory from STAN-CONICET, this 
can be the method of choice even though it lacked enough sensitivity to detect this marker in all 
newly onset T1DM patients. 
 
Fig. 5. Integrated GADA results for children and adolescents with newly diagnosed T1DM. 
The results obtained by RBA, ELISA, and FloCMIA protocol C are presented as Venn’s diagrams. 
4. Conclusion 
From the experimental evidence presented herein, it may be concluded that microsphere-based 
immunoassays performed on Flow Cytometers constitute an innovative and cost-effective 
alternative to traditional determination of GADA by RBA and/or ELISA. Its advantages can be 
resumed as follows: i) highly sensitive detection due to fluorescent-labeling, ii) the use of easy-to-
produce recombinant proteins from prokaryotic cells, iii) intact immunoreactivity of antigens after 
adsorption on microspheres, iv) the combination of solid and fluid phase interactions, v) a good 
specificity, vi) a wide dynamic range, vii) a small sample volume required, viii) low cost and 
environmentally harmless and ix) applicable in most medium-complexity laboratories.  
In addition, the methods based on FloCMIA have also the potential to determine various humoral 
markers simultaneously. This is possible by using microspheres of variable diameters 
distinguishable by Flow Cytometers. Measuring simultaneously a number of related analytes 
(multiplexing) overcomes some of the limitations of conventional single and combined methods and 
appears to be advantageous to assess markers exhibiting differential profiles in the multiple variants 
and presentations of DM. 
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Figure captions 
Fig. 1. Schematic representations of alternative FloCMIA protocols for GADA detection. Four 
µm microspheres-TrxGAD65 were used as the solid phase.  
Fig. 2. GADA results from normal human sera (controls) and diabetic patients’ sera from 
STAN-CONICET. The results, expressed as SDs, were obtained by RBA (a), ELISA (b) and 
FloCMIA protocols (c, i. protocol A, ii. Protocol B and iii. Protocol C). The cut-off value for each 
assay is indicated by a dotted line. 
Fig. 3. Integrated GADA results for diabetic patients’ sera from STAN-CONICET. The results 
obtained by RBA, ELISA, and FloCMIA protocol A (a), protocol B (b) and protocol C (c) are 
presented as Venn’s diagrams. 
Fig. 4. GADA results from normal human sera (controls) and children and adolescents with 
newly diagnosed T1DM. The results, expressed as SDs, were obtained by RBA (a), ELISA (b) and 
FloCMIA protocol C (c). The cut-off value for each assay is indicated by a dotted line. 
Fig. 5. Integrated GADA results for children and adolescents with newly diagnosed T1DM. 
The results obtained by RBA, ELISA, and FloCMIA protocol C are presented as Venn’s diagrams. 
Table 1. Analytical parameters from normal human sera and patients’ sera from STAN-
CONICET. The results were obtained by RBA, ELISA and FloCMIA protocols A, B and C. 
Table 2. Analytical parameters from normal human sera and sera from children and 
adolescents with newly diagnosed T1DM. The results were obtained by RBA, ELISA and 
FloCMIA protocol C. 
Electronic Supplementary Figure 1. Four µm microspheres-TrxGAD65 set. Population of 
microspheres seen in FSC vs. SSC dot plot for gating purposes (a), and FL1 vs. number of events 
histogram (b), for measuring of fluorescence (representative signals from normal human serum and 
diabetic patient’s serum are shown). 
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Electronic Supplementary Figure 2. Flowchart of experimental protocols for FloCMIA A, B and 
C. 
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